Clinical trials: Schizo-Affective Type of Psychosis
Schizophrenia, Schizoaffective Disorder
Bioavailability of LY03004 and Risperdal® Consta®
This study is to assess the bioavailability of LY03004 compared to Risperdal Consta as well as the evaluate the safety and tolerability and preliminary efficacy of LY03004 with repeat injections
- Trial name
- NCT02091388
- Testing
- LY03004, Risperdal® Consta®
- Where
- 10 sites in United States
- Volunteers
- 108 people
- Sponsor
- Luye Pharma Group Ltd.
Schizophrenia, Schizoaffective Disorder
Trial to Evaluate the Effects of OPC-34712 on QT/QTc in Subjects With Schizophrenia or Schizoaffective Disorder
The purpose of this study is to establish pharmacodynamics (PD), pharmacokinetics (PK), and adverse event (AE) profile of OPC-34712 administered to schizophrenic/schizoaffective subjects.
- Trial name
- NCT01423916
- Testing
- OPC-34712 (4mg), Moxifloxacin, OPC-34712 (12mg)
- Where
- 8 sites in United States
- Volunteers
- 218 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia, Schizoaffective Disorder
Safety Study of Olanzapine and a Comparator in Patients With Schizophrenia and Schizoaffective Disorder
This study will assess whether olanzapine and/or risperidone affect the way the human body uses sugar in the blood.
- Trial name
- NCT00190749
- Testing
- olanzapine, risperidone
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- Eli Lilly and Company
Schizophrenia, Schizoaffective Disorder
Study on the Safety of Risperidone on Obese or Overweight Patients With Schizophrenia
The purpose of this study is to evaluate the safety of risperidone treatment in patients who are overweight and/or obese.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder
- Trial name
- NCT00511628
- Testing
- Risperidone
- Volunteers
- 1,717 people
- Sponsor
- Janssen-Cilag, S.A.